Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · IEX Real-Time Price · USD
0.780
+0.040 (5.39%)
At close: Apr 18, 2024, 4:00 PM
0.752
-0.028 (-3.64%)
After-hours: Apr 18, 2024, 6:41 PM EDT

Forte Biosciences Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 202320222021202020192018201720162015
Cash & Equivalents
37.1341.142.0458.776.9440.8135.935.518.15
Short-Term Investments
0000055.2752.7925.7450.76
Cash & Cash Equivalents
37.1341.142.0458.776.9496.0988.7331.2558.91
Cash Growth
-9.67%-2.25%-28.45%746.88%-92.78%8.30%183.97%-46.96%-
Other Current Assets
1.20.410.481.130.571.661.91.221.3
Total Current Assets
38.3341.5142.5259.97.5197.7590.6332.4660.21
Property, Plant & Equipment
0.11000.10.153.971.220.740.45
Other Long-Term Assets
0.540.490.791.2401.360.232.151.53
Total Long-Term Assets
0.650.490.791.340.155.331.442.891.97
Total Assets
38.984243.3161.247.66103.0892.0735.3562.18
Accounts Payable
1.421.150.951.241.573.41.951.671.3
Deferred Revenue
000000.040.070.110.16
Current Debt
0000007.27.20.6
Other Current Liabilities
2.242.030.811.020.3413.098.115.43.87
Total Current Liabilities
3.673.181.762.261.9116.5317.3314.385.94
Long-Term Debt
0000026.23.6313.7816.87
Other Long-Term Liabilities
000010.522.20.040.190.28
Total Long-Term Liabilities
000010.5228.43.6613.9717.16
Total Liabilities
3.673.181.762.2612.4344.9420.9928.3623.09
Total Debt
0000026.210.8320.9817.47
Debt Growth
-----142.04%-48.40%20.07%-
Retained Earnings
-118.52-87.04-73.17-51.46-4.97-215.88-166.93-128-94.51
Comprehensive Income
00000-0.02-0.030-0.06
Shareholders' Equity
35.3138.8241.5558.98-4.7758.1571.08-124.42-92.33
Net Cash / Debt
37.1341.142.0458.776.9469.8977.910.2741.44
Net Cash / Debt Growth
-9.67%-2.25%-28.45%746.88%-90.07%-10.29%658.82%-75.23%-
Net Cash Per Share
1.182.363.017.993.2952.2679.9970.00284.85
Working Capital
34.6638.3340.7657.645.5981.2173.318.0854.27
Book Value Per Share
1.122.232.988.02-2.2643.4872.99-848.31-634.70
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).